ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,433.74
0.23%
Dow Jones
38,647.10
-0.17%
US Dollar vs MXN
18.423
0.00%
Brent Oil
82.215
0.29%
Bitcoin
66,791.11
0.05%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. PTC Therapeutics Inc (PTCT)

  7. PTC Therapeutics Inc (PTCT) Noticias

PTCT

PTC Therapeutics (PTCT)

PTC Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PTCT
FechaHoraFuenteTítuloSímboloCompañía
29/05/202407:00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferenceNASDAQ:PTCTPTC Therapeutics Inc
28/05/202407:30PR Newswire (US)PTC Therapeutics Announces Validation of Sepiapterin European MAANASDAQ:PTCTPTC Therapeutics Inc
24/05/202416:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PTCTPTC Therapeutics Inc
22/05/202409:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PTCTPTC Therapeutics Inc
20/05/202411:20PR Newswire (US)PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluationNASDAQ:PTCTPTC Therapeutics Inc
20/05/202406:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PTCTPTC Therapeutics Inc
14/05/202406:30PR Newswire (US)PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™NASDAQ:PTCTPTC Therapeutics Inc
02/05/202407:00PR Newswire (US)PTC Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:PTCTPTC Therapeutics Inc
25/04/202415:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
23/04/202415:30PR Newswire (US)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PTCTPTC Therapeutics Inc
11/04/202407:00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
28/03/202407:30PR Newswire (US)PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMANASDAQ:PTCTPTC Therapeutics Inc
19/03/202406:30PR Newswire (US)PTC Therapeutics Provides Key Regulatory UpdatesNASDAQ:PTCTPTC Therapeutics Inc
29/02/202415:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
15/02/202407:00PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202414:50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PTCTPTC Therapeutics Inc
14/02/202406:13Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PTCTPTC Therapeutics Inc
25/01/202415:05PR Newswire (US)CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination ProcedureNASDAQ:PTCTPTC Therapeutics Inc
08/01/202408:26PR Newswire (US)PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
03/01/202407:00PR Newswire (US)PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:PTCTPTC Therapeutics Inc
05/12/202316:24Dow Jones NewsPTC Therapeutics Gives Updates on Translarna Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
05/12/202315:15PR Newswire (US)PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesNASDAQ:PTCTPTC Therapeutics Inc
07/11/202315:16Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:PTCTPTC Therapeutics Inc
26/10/202315:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PTCTPTC Therapeutics Inc
26/10/202315:05PR Newswire (US)PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial ResultsNASDAQ:PTCTPTC Therapeutics Inc
19/10/202307:00PR Newswire (US)PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 BillionNASDAQ:PTCTPTC Therapeutics Inc
16/10/202315:30PR Newswire (US)PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results NASDAQ:PTCTPTC Therapeutics Inc
29/09/202306:29IH Market NewsFriday’s Wall Street Highlights: New Integrated, Nike, Tesla, Alphabet, and moreNASDAQ:PTCTPTC Therapeutics Inc
28/09/202319:12Dow Jones NewsStocks to Watch: Nike, Novo Integrated, PTC TherapeuticsNASDAQ:PTCTPTC Therapeutics Inc
28/09/202315:30PR Newswire (US)PTC Announces Further Strategic Prioritization and Associated Reduction in WorkforceNASDAQ:PTCTPTC Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PTCT

Su Consulta Reciente

NYSE
MRK
Merck
NYSE
NKE
Nike
COIN
SOLUSD
Solana
CCOM
OILBRENT
Brent Oil
NASDAQ
MSFT
Microsoft
FX
EURMXN
Euro vs MXN
NYSE
BAC
Bank of America
AMEX
SPY
SPDR S&P 500
USOTC
ADDYY
Adidas (QX)
NYSE
XOM
Exxon Mobil
CCOM
SILVER
SILVER
USOTC
RHHBY
Roche (QX)
NYSE
MCD
McDonalds
NYSE
KO
Coca Cola
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados